Acumen Pharmaceuticals Inc (ABOS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Daniel J. O'Connell
Employees:
20
4435 NORTH FIRST STREET, SUITE 360, LIVERMORE, CA 94551
925-368-8508

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage.

Data derived from most recent annual or quarterly report
Market Cap 161.202 Million Shares Outstanding40.503 Million Avg 30-day Volume 90.668 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.26
Price to Revenue0.0 Debt to Equity0.0 EBITDA-38.772 Million
Price to Book Value2.0658 Operating Margin0.0 Enterprise Value206.05 Million
Current Ratio30.631 EPS Growth0 Quick Ratio30.273
1 Yr BETA 1.2608 52-week High/Low 10.97 / 3.02 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score36.2868 Free Cash Flow to Firm 0
Earnings Report2023-03-27
View SEC Filings from ABOS instead.

View recent insider trading info

Acumen Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ABOS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABOS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-18 by ZUGA MATT
  • 4: filed on 2023-01-18 by SIEMERS ERIC
  • 4: filed on 2023-01-18 by OCONNELL DANIEL JOSEPH
  • 4: filed on 2023-01-18 by MEISNER DEREK M
  • 4: filed on 2023-01-18 by BARTON RUSSELL
  • 4: filed on 2023-01-04 by PORTER DERRELL
  • 3: filed on 2023-01-04 by PORTER DERRELL
  • 4: filed on 2023-01-03 by ZUGA MATT
  • 4: filed on 2022-09-07 by MEISNER DEREK M
  • 3: filed on 2022-09-07 by MEISNER DEREK M

    • Events (8k)

  • 8-K: filed on 2023-03-15:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-01:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-01:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MEISNER DEREK M CHIEF LEGAL OFFICE & CORP SEC

    • Officer
    		 147,600 2023-01-17 3

    ZUGA MATT CFO AND CHIEF BUSINESS OFFICER

    • Officer
    		 260,487 2023-01-17 2

    OCONNELL DANIEL JOSEPH PRESIDENT AND CEO

    • Officer
    • Director
    		 589,185 2023-01-17 1

    SIEMERS ERIC CHIEF MEDICAL OFFICER

    • Officer
    		 146,900 2023-01-17 1

    BARTON RUSSELL CHIEF OPERATING OFFICER

    • Officer
    		 146,900 2023-01-17 1

    PORTER DERRELL

    • Director
    		 0 2023-01-04 2

    RA CAPITAL MANAGEMENT, L.P.

    RA CAPITAL HEALTHCARE FUND LP

    RA CAPITAL NEXUS FUND II, L.P.

    KOLCHINSKY PETER

    SHAH RAJEEV M.

    • Director
    • 10% Owner
    		 25,000 2022-06-15 1

    DRAPKIN KIMBERLEE C

    • Director
    		 25,000 2022-06-15 3

    IVES JEFFREY L.

    • Director
    		 25,000 2022-06-15 1

    STALFORT JOHN A III

    • Director
    		 25,000 2022-06-15 1

    SEVIGNY JEFFREY

    • Director
    		 25,000 2022-06-15 1

    STOPPEL LAURA

    • Director
    		 25,000 2022-06-15 1

    FOUNTAIN NATHAN B

    • Director
    		 25,000 2022-06-15 1

    MANNING PAUL B

    • 10% Owner
    		 No longer subject to file 2021-07-06 0

    HARDIE ROBERT D.

    • 10% Owner
    		 No longer subject to file 2021-07-06 0

    SANDS CAPITAL VENTURES DISCOVERY FUND III, L.P.

    SANDS CAPITAL GLOBAL VENTURE FUND II, L.P.

    SANDS CAPITAL LIFE SCIENCES PULSE FUND, LLC

    SANDS FRANK M.

    • 10% Owner
    		 No longer subject to file 2021-07-06 0

    HAYASHI SCOTT CHIEF FINANCIAL OFFICER

    • Officer
    		 6,923 2007-04-23 0

    KOGOD DENNIS

    • Director
    		 25,000 2007-01-16 0

    VIERLING JOHN

    • Director
    		 20,000 2007-01-11 0

    STOVER JACK E

    • Director
    		 20,000 2007-01-11 0

    SEOH THOMAS C

    • Director
    		 25,000 2007-01-11 0

    TULLY THOMAS M

    • Director
    		 30,000 2007-01-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 17:15:03 UTC -5.3451 10.1651 300000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 16:45:03 UTC -5.2344 10.0544 300000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 16:15:03 UTC -5.2344 10.0544 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 15:45:03 UTC -5.2344 10.0544 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 15:15:03 UTC -5.2344 10.0544 300000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 14:45:03 UTC -5.2344 10.0544 300000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 14:15:03 UTC -5.2344 10.0544 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 13:45:03 UTC -4.8035 9.3735 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 13:15:04 UTC -4.8035 9.3735 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-24 12:45:03 UTC -4.8035 9.3735 200000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 22:15:04 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 21:45:04 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 21:15:04 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 20:45:03 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 20:15:03 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 19:45:03 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 19:15:03 UTC -4.8035 9.3735 650000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 18:45:04 UTC -4.8035 9.3735 650000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 18:15:03 UTC -4.8035 9.3735 600000
    ACUMEN PHARMACEUTICALS INC ABOS 2023-03-23 17:45:03 UTC -4.8035 9.3735 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments